{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T02:08:41Z","timestamp":1793758121247,"version":"4.6.1"},"reference-count":87,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T00:00:00Z","timestamp":1769817600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T00:00:00Z","timestamp":1769817600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100005612","name":"Shionogi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005612","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s40121-026-01301-y","type":"journal-article","created":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T05:48:10Z","timestamp":1769838490000},"page":"835-857","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Role of Cefiderocol in the Treatment of Carbapenem-Resistant Nonfermenting Gram-Negative Bacilli (Acinetobacter baumannii, Pseudomonas aeruginosa, and Stenotrophomonas maltophilia) Infections: An Expert Statement"],"prefix":"10.1007","volume":"15","author":[{"given":"Alexandre","family":"Bleibtreu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youssef","family":"Bennis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5843-4819","authenticated-orcid":false,"given":"Aur\u00e9lien","family":"Dinh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herv\u00e9","family":"Dupont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Friggeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katy","family":"Jeannot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Kipnis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Ralph","family":"Zahar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"CoRIS Cohort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,31]]},"reference":[{"key":"1301_CR1","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1016\/S0140-6736(24)01867-1","volume":"404","author":"GBD 2021 Antimicrobial Resistance Collaborators","year":"2024","unstructured":"GBD 2021 Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance 1990\u20132021: a systematic analysis with forecasts to 2050. Lancet. 2024;404:1199\u2013226. https:\/\/doi.org\/10.1016\/S0140-6736(24)01867-1.","journal-title":"Lancet"},{"key":"1301_CR2","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1093\/cid\/ciab1013","volume":"74","author":"PD Tamma","year":"2022","unstructured":"Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious Diseases Society of America guidance on the treatment of AmpC \u03b2-lactamase-producing enterobacterales, carbapenem-resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia infections. Clin Infect Dis. 2022;74:2089\u2013114. https:\/\/doi.org\/10.1093\/cid\/ciab1013.","journal-title":"Clin Infect Dis"},{"key":"1301_CR3","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1093\/cid\/ciab757","volume":"74","author":"S Ong\u2019uti","year":"2022","unstructured":"Ong\u2019uti S, Czech M, Robilotti E, Holubar M. Cefiderocol: a new cephalosporin stratagem against multidrug-resistant gram-negative bacteria. Clin Infect Dis. 2022;74:1303\u201312. https:\/\/doi.org\/10.1093\/cid\/ciab757.","journal-title":"Clin Infect Dis"},{"key":"1301_CR4","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s40265-019-1055-2","volume":"79","author":"GG Zhanel","year":"2019","unstructured":"Zhanel GG, Golden AR, Zelenitsky S, Wiebe K, Lawrence CK, Adam HJ, et\u00a0al. Cefiderocol: a siderophore cephalosporin with activity against carbapenem-resistant and multidrug-resistant gram-negative bacilli. Drugs. 2019;79:271\u201389. https:\/\/doi.org\/10.1007\/s40265-019-1055-2.","journal-title":"Drugs"},{"key":"1301_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.896971","volume":"13","author":"C Wang","year":"2022","unstructured":"Wang C, Yang D, Wang Y, Ni W. Cefiderocol for the treatment of multidrug-resistant gram-negative bacteria: a systematic review of currently available evidence. Front Pharmacol. 2022;13:896971. https:\/\/doi.org\/10.3389\/fphar.2022.896971.","journal-title":"Front Pharmacol"},{"key":"1301_CR6","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.02712-21","volume":"10","author":"D Shortridge","year":"2022","unstructured":"Shortridge D, Streit JM, Mendes R, Castanheira M. In vitro activity of cefiderocol against U.S. and European gram-negative clinical isolates collected in 2020 as part of the SENTRY antimicrobial surveillance program. Microbiol Spectr. 2022;10:e0271221. https:\/\/doi.org\/10.1128\/spectrum.02712-21.","journal-title":"Microbiol Spectr"},{"key":"1301_CR7","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.ijantimicag.2018.10.007","volume":"53","author":"KM Kazmierczak","year":"2019","unstructured":"Kazmierczak KM, Tsuji M, Wise MG, Hackel M, Yamano Y, Echols R, et\u00a0al. In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible gram-negative bacilli, including serine carbapenemase- and metallo-\u03b2-lactamase-producing isolates (SIDERO-WT-2014 Study). Int J Antimicrob Agents. 2019;53:177\u201384. https:\/\/doi.org\/10.1016\/j.ijantimicag.2018.10.007.","journal-title":"Int J Antimicrob Agents"},{"key":"1301_CR8","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.cmi.2021.11.025","volume":"28","author":"M Paul","year":"2022","unstructured":"Paul M, Carrara E, Retamar P, T\u00e4ngd\u00e9n T, Bitterman R, Bonomo RA, et\u00a0al. European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant gram-negative bacilli (endorsed by European society of intensive care medicine). Clin Microbiol Infect. 2022;28:521\u201347. https:\/\/doi.org\/10.1016\/j.cmi.2021.11.025.","journal-title":"Clin Microbiol Infect"},{"key":"1301_CR9","unstructured":"Recommandations. n.d. https:\/\/www.infectiologie.com\/fr\/recommandations.html. Accessed 12 Aug 2025."},{"key":"1301_CR10","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01117-20","volume":"65","author":"D Fournier","year":"2021","unstructured":"Fournier D, Carri\u00e8re R, Bour M, Grisot E, Triponney P, Muller C, et\u00a0al. Mechanisms of resistance to ceftolozane\/tazobactam in Pseudomonas aeruginosa: results of the GERPA multicenter study. Antimicrob Agents Chemother. 2021;65:e01117-20. https:\/\/doi.org\/10.1128\/AAC.01117-20.","journal-title":"Antimicrob Agents Chemother"},{"key":"1301_CR11","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1007\/s00134-022-06944-2","volume":"49","author":"A Tabah","year":"2023","unstructured":"Tabah A, Buetti N, Staiquly Q, Ruckly S, Akova M, Aslan AT, et\u00a0al. Epidemiology and outcomes of hospital-acquired bloodstream infections in intensive care unit patients: the EUROBACT-2 international cohort study. Intensive Care Med. 2023;49:178\u201390. https:\/\/doi.org\/10.1007\/s00134-022-06944-2.","journal-title":"Intensive Care Med"},{"key":"1301_CR12","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1017\/S0950268807009478","volume":"136","author":"ME Falagas","year":"2008","unstructured":"Falagas ME, Karveli EA, Siempos II, Vardakas KZ. Acinetobacter infections: a growing threat for critically ill patients. Epidemiol Infect. 2008;136:1009\u201319. https:\/\/doi.org\/10.1017\/S0950268807009478.","journal-title":"Epidemiol Infect"},{"key":"1301_CR13","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.jhin.2025.05.010","volume":"162","author":"S Nasser","year":"2025","unstructured":"Nasser S, Alnasser Z, Aljuhani O, Alharbi A, Rice J, Alharthi AF, et\u00a0al. Exploring infection risk factors and multi-drug-resistant organisms (MDROs) in burn intensive care units: a multi-centre case-control study. J Hosp Infect. 2025;162:186\u201396. https:\/\/doi.org\/10.1016\/j.jhin.2025.05.010.","journal-title":"J Hosp Infect"},{"key":"1301_CR14","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1097\/CCM.0000000000003553","volume":"47","author":"W Ibn Saied","year":"2019","unstructured":"Ibn Saied W, Mourvillier B, Cohen Y, Ruckly S, Reignier J, Marcotte G, et\u00a0al. A comparison of the mortality risk associated with ventilator-acquired bacterial pneumonia and nonventilator ICU-acquired bacterial pneumonia. Crit Care Med. 2019;47:345\u201352. https:\/\/doi.org\/10.1097\/CCM.0000000000003553.","journal-title":"Crit Care Med"},{"key":"1301_CR15","doi-asserted-by":"publisher","first-page":"215","DOI":"10.3109\/00365548.2013.871644","volume":"46","author":"J-F Soubirou","year":"2014","unstructured":"Soubirou J-F, Gault N, Alfaiate T, Lolom I, Tubach F, Andremont A, et\u00a0al. Ventilator-associated pneumonia due to carbapenem-resistant gram-negative bacilli in an intensive care unit without carbapenemase-producing Enterobacteriaceae or epidemic Acinetobacter baumannii. Scand J Infect Dis. 2014;46:215\u201320. https:\/\/doi.org\/10.3109\/00365548.2013.871644.","journal-title":"Scand J Infect Dis"},{"key":"1301_CR16","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.jinf.2019.09.012","volume":"79","author":"S Mohd Sazlly Lim","year":"2019","unstructured":"Mohd Sazlly Lim S, Zainal Abidin A, Liew SM, Roberts JA, Sime FB. The global prevalence of multidrug-resistance among Acinetobacter baumannii causing hospital-acquired and ventilator-associated pneumonia and its associated mortality: a systematic review and meta-analysis. J Infect. 2019;79:593\u2013600. https:\/\/doi.org\/10.1016\/j.jinf.2019.09.012.","journal-title":"J Infect"},{"key":"1301_CR17","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlaf134","volume":"7","author":"A Boutzoukas","year":"2025","unstructured":"Boutzoukas A, Doi Y. The global epidemiology of carbapenem-resistant Acinetobacter baumannii. JAC Antimicrob Resist. 2025;7:dlaf134. https:\/\/doi.org\/10.1093\/jacamr\/dlaf134.","journal-title":"JAC Antimicrob Resist"},{"key":"1301_CR18","unstructured":"SPF. Surveillance de la consommation d\u2019antibiotiques et des r\u00e9sistances bact\u00e9riennes en \u00e9tablissement de sant\u00e9. Mission Spares. R\u00e9sultats 2021. n.d. https:\/\/www.santepubliquefrance.fr\/import\/surveillance-de-la-consommation-d-antibiotiques-et-des-resistances-bacteriennes-en-etablissement-de-sante.-mission-spares.-resultats-2021. Accessed 12 Aug 2025."},{"key":"1301_CR19","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.03836-23","volume":"12","author":"A Santerre Henriksen","year":"2024","unstructured":"Santerre Henriksen A, Jeannot K, Oliver A, Perry JD, Pletz MW, Stefani S, et\u00a0al. In vitro activity of cefiderocol against European Pseudomonas aeruginosa and Acinetobacter spp., including isolates resistant to meropenem and recent \u03b2-lactam\/\u03b2-lactamase inhibitor combinations. Microbiol Spectr. 2024;12:e03836-23. https:\/\/doi.org\/10.1128\/spectrum.03836-23.","journal-title":"Microbiol Spectr"},{"key":"1301_CR20","unstructured":"CRAB Carbapenem-resistant Acinetobacter baumannii. n.d."},{"key":"1301_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-025-10749-1","volume":"25","author":"TP Lodise","year":"2025","unstructured":"Lodise TP, Nguyen ST, Margiotta C, Cai B. Clinical burden of Acinetobacter baumannii, including carbapenem-resistant A. baumannii, in hospitalized adult patients in the USA between 2018 and 2022. BMC Infect Dis. 2025;25:549. https:\/\/doi.org\/10.1186\/s12879-025-10749-1.","journal-title":"BMC Infect Dis"},{"key":"1301_CR22","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00665-23","volume":"67","author":"SH Moussa","year":"2023","unstructured":"Moussa SH, Shapiro AB, McLeod SM, Iyer R, Carter NM, Tsai Y-K, et\u00a0al. Molecular drivers of resistance to sulbactam-durlobactam in contemporary clinical isolates of Acinetobacter baumannii. Antimicrob Agents Chemother. 2023;67:e00665-23. https:\/\/doi.org\/10.1128\/aac.00665-23.","journal-title":"Antimicrob Agents Chemother"},{"key":"1301_CR23","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.1007\/s40121-021-00541-4","volume":"10","author":"JC Abdul-Mutakabbir","year":"2021","unstructured":"Abdul-Mutakabbir JC, Griffith NC, Shields RK, Tverdek FP, Escobar ZK. Contemporary perspective on the treatment of Acinetobacter baumannii infections: insights from the Society of Infectious Diseases Pharmacists. Infect Dis Ther. 2021;10:2177\u2013202. https:\/\/doi.org\/10.1007\/s40121-021-00541-4.","journal-title":"Infect Dis Ther"},{"key":"1301_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics12071172","volume":"12","author":"H Seifert","year":"2023","unstructured":"Seifert H, M\u00fcller C, Stefanik D, Higgins PG, Wohlfarth E, Kresken M. In vitro activity of cefiderocol against a global collection of carbapenem-resistant Acinetobacter baumannii isolates. Antibiotics. 2023;12:1172. https:\/\/doi.org\/10.3390\/antibiotics12071172.","journal-title":"Antibiotics"},{"key":"1301_CR25","doi-asserted-by":"publisher","first-page":"652.e1","DOI":"10.1016\/j.cmi.2022.12.021","volume":"29","author":"L Devoos","year":"2023","unstructured":"Devoos L, Biguenet A, Rousselot J, Bour M, Pl\u00e9siat P, Fournier D, et\u00a0al. Performance of discs, sensititre EUMDROXF microplates and MTS gradient strips for the determination of the susceptibility of multidrug-resistant Pseudomonas aeruginosa to cefiderocol. Clin Microbiol Infect. 2023;29:652.e1-652.e8. https:\/\/doi.org\/10.1016\/j.cmi.2022.12.021.","journal-title":"Clin Microbiol Infect"},{"key":"1301_CR26","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1007\/s10096-023-04631-8","volume":"42","author":"D Fournier","year":"2023","unstructured":"Fournier D, Triponney P, Gabriel L, Pl\u00e9siat P, Jeannot K, Potron A. Evaluation of 5 rapid colorimetric and immunochromatographic tests for the detection of carbapenemases in Pseudomonas aeruginosa and Acinetobacter spp. isolates. Eur J Clin Microbiol Infect Dis. 2023;42:1043\u20135. https:\/\/doi.org\/10.1007\/s10096-023-04631-8.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"1301_CR27","unstructured":"Clinical & Laboratory Standards Institute | CLSI. n.d. https:\/\/clsi.org\/. Accessed 3 Nov 2025."},{"key":"1301_CR28","unstructured":"eucast: Clinical breakpoints and dosing of antibiotics. n.d. https:\/\/www.eucast.org\/clinical_breakpoints. Accessed 8 Nov 2024."},{"key":"1301_CR29","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/S1473-3099(20)30796-9","volume":"21","author":"M Bassetti","year":"2021","unstructured":"Bassetti M, Echols R, Matsunaga Y, Ariyasu M, Doi Y, Ferrer R, et\u00a0al. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial. Lancet Infect Dis. 2021;21:226\u201340. https:\/\/doi.org\/10.1016\/S1473-3099(20)30796-9.","journal-title":"Lancet Infect Dis"},{"key":"1301_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2023.107047","volume":"63","author":"M Gatti","year":"2024","unstructured":"Gatti M, Cosentino F, Giannella M, Viale P, Pea F. Clinical efficacy of cefiderocol-based regimens in patients with carbapenem-resistant Acinetobacter baumannii infections: a systematic review with meta-analysis. Int J Antimicrob Agents. 2024;63:107047. https:\/\/doi.org\/10.1016\/j.ijantimicag.2023.107047.","journal-title":"Int J Antimicrob Agents"},{"key":"1301_CR31","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02031-18","volume":"63","author":"R Nakamura","year":"2019","unstructured":"Nakamura R, Ito-Horiyama T, Takemura M, Toba S, Matsumoto S, Ikehara T, et\u00a0al. In vivo pharmacodynamic study of cefiderocol, a novel parenteral siderophore cephalosporin, in murine thigh and lung infection models. Antimicrob Agents Chemother. 2019;63:e02031-18. https:\/\/doi.org\/10.1128\/AAC.02031-18.","journal-title":"Antimicrob Agents Chemother"},{"key":"1301_CR32","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01437-20","volume":"65","author":"N Kawaguchi","year":"2021","unstructured":"Kawaguchi N, Katsube T, Echols R, Wajima T. Population pharmacokinetic and pharmacokinetic\/pharmacodynamic analyses of cefiderocol, a parenteral siderophore cephalosporin, in patients with pneumonia, bloodstream infection\/sepsis, or complicated urinary tract infection. Antimicrob Agents Chemother. 2021;65:e01437-20. https:\/\/doi.org\/10.1128\/AAC.01437-20.","journal-title":"Antimicrob Agents Chemother"},{"key":"1301_CR33","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s13054-019-2378-9","volume":"23","author":"R Guilhaumou","year":"2019","unstructured":"Guilhaumou R, Benaboud S, Bennis Y, Dahyot-Fizelier C, Dailly E, Gandia P, et\u00a0al. Optimization of the treatment with beta-lactam antibiotics in critically ill patients-guidelines from the French Society of Pharmacology and Therapeutics (Soci\u00e9t\u00e9 Fran\u00e7aise de Pharmacologie et Th\u00e9rapeutique-SFPT) and the French Society of Anaesthesia and Intensive Care Medicine (Soci\u00e9t\u00e9 Fran\u00e7aise d\u2019Anesth\u00e9sie et R\u00e9animation-SFAR). Crit Care. 2019;23:104. https:\/\/doi.org\/10.1186\/s13054-019-2378-9.","journal-title":"Crit Care"},{"key":"1301_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-024-04911-5","volume":"28","author":"M Gatti","year":"2024","unstructured":"Gatti M, Cojutti PG, Pea F. Impact of attaining aggressive vs. conservative PK\/PD target on the clinical efficacy of beta-lactams for the treatment of gram-negative infections in the critically ill patients: a systematic review and meta-analysis. Crit Care. 2024;28:123. https:\/\/doi.org\/10.1186\/s13054-024-04911-5.","journal-title":"Crit Care"},{"key":"1301_CR35","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlab174","volume":"3","author":"R Pascale","year":"2021","unstructured":"Pascale R, Pasquini Z, Bartoletti M, Caiazzo L, Fornaro G, Bussini L, et\u00a0al. Cefiderocol treatment for carbapenem-resistant Acinetobacter baumannii infection in the ICU during the COVID-19 pandemic: a multicentre cohort study. JAC Antimicrob Resist. 2021;3:dlab174. https:\/\/doi.org\/10.1093\/jacamr\/dlab174.","journal-title":"JAC Antimicrob Resist"},{"key":"1301_CR36","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics12061048","volume":"12","author":"L Dalfino","year":"2023","unstructured":"Dalfino L, Stufano M, Bavaro DF, Diella L, Belati A, Stolfa S, et\u00a0al. Effectiveness of first-line therapy with old and novel antibiotics in ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii: a real life, prospective, observational, single-center study. Antibiotics. 2023;12:1048. https:\/\/doi.org\/10.3390\/antibiotics12061048.","journal-title":"Antibiotics"},{"key":"1301_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2023.106825","volume":"62","author":"A Russo","year":"2023","unstructured":"Russo A, Bruni A, Gull\u00ec S, Borrazzo C, Quirino A, Lionello R, et\u00a0al. Efficacy of cefiderocol- vs colistin-containing regimen for treatment of bacteraemic ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii in patients with COVID-19. Int J Antimicrob Agents. 2023;62:106825. https:\/\/doi.org\/10.1016\/j.ijantimicag.2023.106825.","journal-title":"Int J Antimicrob Agents"},{"key":"1301_CR38","doi-asserted-by":"publisher","DOI":"10.1128\/aac.02142-21","volume":"66","author":"M Falcone","year":"2022","unstructured":"Falcone M, Tiseo G, Leonildi A, Della Sala L, Vecchione A, Barnini S, et\u00a0al. Cefiderocol-compared to colistin-based regimens for the treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2022;66:e0214221. https:\/\/doi.org\/10.1128\/aac.02142-21.","journal-title":"Antimicrob Agents Chemother"},{"key":"1301_CR39","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms11040984","volume":"11","author":"M Mazzitelli","year":"2023","unstructured":"Mazzitelli M, Gregori D, Sasset L, Trevenzoli M, Scaglione V, Lo Menzo S, et\u00a0al. Cefiderocol-based versus colistin-based regimens for severe carbapenem-resistant Acinetobacter baumannii infections: a propensity score-weighted, retrospective cohort study during the first two years of the COVID-19 pandemic. Microorganisms. 2023;11:984. https:\/\/doi.org\/10.3390\/microorganisms11040984.","journal-title":"Microorganisms"},{"key":"1301_CR40","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.02347-22","volume":"10","author":"S Stracquadanio","year":"2022","unstructured":"Stracquadanio S, Bonomo C, Marino A, Bongiorno D, Privitera GF, Bivona DA, et\u00a0al. Acinetobacter baumannii and cefiderocol, between cidality and adaptability. Microbiol Spectr. 2022;10:e02347-22. https:\/\/doi.org\/10.1128\/spectrum.02347-22.","journal-title":"Microbiol Spectr"},{"key":"1301_CR41","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01128-20","volume":"64","author":"S Matsumoto","year":"2020","unstructured":"Matsumoto S, Kanazawa S, Sato T, Yamano Y. Activities of cefiderocol with simulated human plasma concentrations against carbapenem-resistant gram-negative bacilli in an in vitro chemostat model. Antimicrob Agents Chemother. 2020;64:10.1128\/aac.01128-20. https:\/\/doi.org\/10.1128\/aac.01128-20.","journal-title":"Antimicrob Agents Chemother"},{"key":"1301_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2024.01.012","volume":"88","author":"L Onorato","year":"2024","unstructured":"Onorato L, de Luca I, Monari C, Coppola N. Cefiderocol either in monotherapy or combination versus best available therapy in the treatment of carbapenem-resistant Acinetobacter baumannii infections: a systematic review and meta-analysis. J Infect. 2024;88:106113. https:\/\/doi.org\/10.1016\/j.jinf.2024.01.012.","journal-title":"J Infect"},{"key":"1301_CR43","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1002\/jcph.841","volume":"57","author":"T Katsube","year":"2017","unstructured":"Katsube T, Echols R, Arjona Ferreira JC, Krenz HK, Berg JK, Galloway C. Cefiderocol, a siderophore cephalosporin for gram-negative bacterial infections: pharmacokinetics and safety in subjects with renal impairment. J Clin Pharmacol. 2017;57:584\u201391. https:\/\/doi.org\/10.1002\/jcph.841.","journal-title":"J Clin Pharmacol"},{"key":"1301_CR44","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1093\/jac\/dkae464","volume":"80","author":"S Goutelle","year":"2025","unstructured":"Goutelle S, Ammour N, Ferry T, Schramm F, Lepeule R, Friggeri A. Optimal dosage regimens of cefiderocol administered by short, prolonged or continuous infusion: a PK\/PD simulation study. J Antimicrob Chemother. 2025;80:726\u201330. https:\/\/doi.org\/10.1093\/jac\/dkae464.","journal-title":"J Antimicrob Chemother"},{"key":"1301_CR45","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s40261-023-01257-8","volume":"43","author":"C Prinz","year":"2023","unstructured":"Prinz C, Streit F, Schumann C, Dudakova A, Lanckohr C, Schanz J, et\u00a0al. Feasibility of continuous infusion of cefiderocol in conjunction with the establishment of therapeutic drug monitoring in patients with extensively drug-resistant gram-negative bacteria. Clin Drug Investig. 2023;43:307\u201314. https:\/\/doi.org\/10.1007\/s40261-023-01257-8.","journal-title":"Clin Drug Investig"},{"key":"1301_CR46","doi-asserted-by":"publisher","first-page":"e29","DOI":"10.1136\/ejhpharm-2021-002935","volume":"30","author":"G Loeuille","year":"2023","unstructured":"Loeuille G, Vigneron J, D\u2019Huart E, Charmillon A, Demor\u00e9 B. Physicochemical stability of cefiderocol, a novel siderophore cephalosporin, in syringes at 62.5 mg\/mL for continuous administration in intensive care units. Eur J Hosp Pharm. 2023;30:e29-34. https:\/\/doi.org\/10.1136\/ejhpharm-2021-002935.","journal-title":"Eur J Hosp Pharm"},{"key":"1301_CR47","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.jgar.2021.10.014","volume":"27","author":"M Gatti","year":"2021","unstructured":"Gatti M, Bartoletti M, Cojutti PG, Gaibani P, Conti M, Giannella M, et\u00a0al. A descriptive case series of pharmacokinetic\/pharmacodynamic target attainment and microbiological outcome in critically ill patients with documented severe extensively drug-resistant Acinetobacter baumannii bloodstream infection and\/or ventilator-associated pneumonia treated with cefiderocol. J Glob Antimicrob Resist. 2021;27:294\u20138. https:\/\/doi.org\/10.1016\/j.jgar.2021.10.014.","journal-title":"J Glob Antimicrob Resist"},{"key":"1301_CR48","doi-asserted-by":"publisher","DOI":"10.1186\/s12941-024-00685-4","volume":"23","author":"N Bostanghadiri","year":"2024","unstructured":"Bostanghadiri N, Sholeh M, Navidifar T, Dadgar-Zankbar L, Elahi Z, van Belkum A, et\u00a0al. Global mapping of antibiotic resistance rates among clinical isolates of Stenotrophomonas maltophilia: a systematic review and meta-analysis. Ann Clin Microbiol Antimicrob. 2024;23:26. https:\/\/doi.org\/10.1186\/s12941-024-00685-4.","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"1301_CR49","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1163439","volume":"10","author":"M Banar","year":"2023","unstructured":"Banar M, Sattari-Maraji A, Bayatinejad G, Ebrahimi E, Jabalameli L, Beigverdi R, et\u00a0al. Global prevalence and antibiotic resistance in clinical isolates of Stenotrophomonas maltophilia: a systematic review and meta-analysis. Front Med (Lausanne). 2023;10:1163439. https:\/\/doi.org\/10.3389\/fmed.2023.1163439.","journal-title":"Front Med (Lausanne)"},{"key":"1301_CR50","doi-asserted-by":"publisher","DOI":"10.1186\/cc5063","volume":"10","author":"S Nseir","year":"2006","unstructured":"Nseir S, Di Pompeo C, Brisson H, Dewavrin F, Tissier S, Diarra M, et\u00a0al. Intensive care unit-acquired Stenotrophomonas maltophilia: incidence, risk factors, and outcome. Crit Care. 2006;10:R143. https:\/\/doi.org\/10.1186\/cc5063.","journal-title":"Crit Care"},{"key":"1301_CR51","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1111\/resp.14059","volume":"26","author":"H Lee","year":"2021","unstructured":"Lee H, Choi H, Chalmers JD, Dhar R, Nguyen TQ, Visser SK, et\u00a0al. Characteristics of bronchiectasis in Korea: first data from the Korean Multicentre Bronchiectasis Audit and Research Collaboration registry and comparison with other international registries. Respirology. 2021;26:619\u201321. https:\/\/doi.org\/10.1111\/resp.14059.","journal-title":"Respirology"},{"key":"1301_CR52","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.cmi.2023.08.029","volume":"30","author":"S Karakonstantis","year":"2024","unstructured":"Karakonstantis S, Rousaki M, Vassilopoulou L, Kritsotakis EI. Global prevalence of cefiderocol non-susceptibility in Enterobacterales, Pseudomonas aeruginosa, Acinetobacter baumannii, and Stenotrophomonas maltophilia: a systematic review and meta-analysis. Clin Microbiol Infect. 2024;30:178\u201388. https:\/\/doi.org\/10.1016\/j.cmi.2023.08.029.","journal-title":"Clin Microbiol Infect"},{"key":"1301_CR53","unstructured":"eucast: Guidance on Stenotrophomonas maltophilia\u2014Updated November, 2024. n.d. https:\/\/www.eucast.org\/eucast_news\/news_singleview?tx_ttnews%5Btt_news%5D=617&cHash=9399cabfa2f161e98e4eb35a1fd9b4a8 . Accessed 12 Aug 2025."},{"key":"1301_CR54","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofad500.2363","volume":"10","author":"S Marcella","year":"2023","unstructured":"Marcella S, Friedman B, Cai B, Verardi S, Gozalo L, Nguyen ST. 2752. Outcomes of patients with Stenotrophomonas maltophilia infections treated with cefiderocol in PROVE (retrospective cefiderocol chart review) study. Open Forum Infect Dis. 2023;10:ofad500.2363. https:\/\/doi.org\/10.1093\/ofid\/ofad500.2363.","journal-title":"Open Forum Infect Dis"},{"key":"1301_CR55","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1007\/s40121-025-01117-2","volume":"14","author":"A Vena","year":"2025","unstructured":"Vena A, Mezzogori L, Castaldo N, Corcione S, Pascale R, Giannella M, et\u00a0al. Cefiderocol for the treatment of nosocomial bloodstream infections caused by Stenotrophomonas maltophilia: a case series and literature review. Infect Dis Ther. 2025;14:657\u201369. https:\/\/doi.org\/10.1007\/s40121-025-01117-2.","journal-title":"Infect Dis Ther"},{"key":"1301_CR56","doi-asserted-by":"publisher","first-page":"553","DOI":"10.3390\/antibiotics13060553","volume":"13","author":"H Barrasa","year":"2024","unstructured":"Barrasa H, Mor\u00e1n MA, Fern\u00e1ndez-Ciriza L, Isla A, Solin\u00eds M\u00c1, Canut-Blasco A, et\u00a0al. Optimizing antibiotic therapy for Stenotrophomonas maltophilia infections in critically ill patients: a pharmacokinetic\/pharmacodynamic approach. Antibiotics (Basel). 2024;13:553. https:\/\/doi.org\/10.3390\/antibiotics13060553.","journal-title":"Antibiotics (Basel)"},{"key":"1301_CR57","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlac040","volume":"4","author":"MF Mojica","year":"2022","unstructured":"Mojica MF, Humphries R, Lipuma JJ, Mathers AJ, Rao GG, Shelburne SA, et\u00a0al. Clinical challenges treating Stenotrophomonas maltophilia infections: an update. JAC Antimicrob Resist. 2022;4:dlac040. https:\/\/doi.org\/10.1093\/jacamr\/dlac040.","journal-title":"JAC Antimicrob Resist"},{"key":"1301_CR58","unstructured":"WHO bacterial priority pathogens list, 2024: bacterial pathogens of public health importance to guide research, development and strategies to prevent and control antimicrobial resistance. n.d. https:\/\/www.who.int\/publications\/i\/item\/9789240093461. Accessed 12 Aug 2025."},{"key":"1301_CR59","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0282276","volume":"18","author":"JA Frem","year":"2023","unstructured":"Frem JA, Doumat G, Kazma J, Gharamti A, Kanj SS, Abou Fayad AG, et\u00a0al. Clinical predictors of mortality in patients with Pseudomonas aeruginosa infection. PLoS ONE. 2023;18:e0282276. https:\/\/doi.org\/10.1371\/journal.pone.0282276.","journal-title":"PLoS ONE"},{"key":"1301_CR60","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0317540","volume":"20","author":"S Corcione","year":"2025","unstructured":"Corcione S, Pinna SM, Vena A, Schenone M, Sanino M, Pascale R, et\u00a0al. Pseudomonas aeruginosa bloodstream infections in internal medicine wards: a large Italian multicenter retrospective study. PLoS ONE. 2025;20:e0317540. https:\/\/doi.org\/10.1371\/journal.pone.0317540.","journal-title":"PLoS ONE"},{"key":"1301_CR61","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1016\/j.cmi.2019.04.005","volume":"25","author":"A Rojas","year":"2019","unstructured":"Rojas A, Palacios-Baena ZR, L\u00f3pez-Cort\u00e9s LE, Rodr\u00edguez-Ba\u00f1o J. Rates, predictors and mortality of community-onset bloodstream infections due to Pseudomonas aeruginosa: systematic review and meta-analysis. Clin Microbiol Infect. 2019;25:964\u201370. https:\/\/doi.org\/10.1016\/j.cmi.2019.04.005.","journal-title":"Clin Microbiol Infect"},{"key":"1301_CR62","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/S1473-3099(24)00648-0","volume":"25","author":"RK Shields","year":"2025","unstructured":"Shields RK, Abbo LM, Ackley R, Aitken SL, Albrecht B, Babiker A, et\u00a0al. Effectiveness of ceftazidime-avibactam versus ceftolozane-tazobactam for multidrug-resistant Pseudomonas aeruginosa infections in the USA (CACTUS): a multicentre, retrospective, observational study. Lancet Infect Dis. 2025;25:574\u201384. https:\/\/doi.org\/10.1016\/S1473-3099(24)00648-0.","journal-title":"Lancet Infect Dis"},{"key":"1301_CR63","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00405-23","volume":"67","author":"TA Almangour","year":"2023","unstructured":"Almangour TA, Ghonem L, Alassiri D, Aljurbua A, Al Musawa M, Alharbi A, et\u00a0al. Ceftolozane-tazobactam versus ceftazidime-avibactam for the treatment of infections caused by multidrug-resistant Pseudomonas aeruginosa: a multicenter cohort study. Antimicrob Agents Chemother. 2023;67:e0040523. https:\/\/doi.org\/10.1128\/aac.00405-23.","journal-title":"Antimicrob Agents Chemother"},{"key":"1301_CR64","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlac131","volume":"5","author":"TT Tran","year":"2023","unstructured":"Tran TT, Cabrera NL, Gonzales-Luna AJ, Carlson TJ, Alnezary F, Miller WR, et\u00a0al. Clinical characteristics, microbiology and outcomes of a cohort of patients treated with ceftolozane\/tazobactam in acute care inpatient facilities, Houston, Texas, USA. JAC Antimicrob Resist. 2023;5:dlac131. https:\/\/doi.org\/10.1093\/jacamr\/dlac131.","journal-title":"JAC Antimicrob Resist"},{"key":"1301_CR65","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofae037","volume":"11","author":"J-F Timsit","year":"2024","unstructured":"Timsit J-F, Mootien J, Akrich B, Bourge X, Brassac I, Castan B, et\u00a0al. Ceftolozane\/tazobactam for the treatment of complicated infections in hospital settings\u2014A French real-world study. Open Forum Infect Dis. 2024;11:ofae037. https:\/\/doi.org\/10.1093\/ofid\/ofae037.","journal-title":"Open Forum Infect Dis"},{"key":"1301_CR66","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.jgar.2022.01.023","volume":"28","author":"TA Almangour","year":"2022","unstructured":"Almangour TA, Aljabri A, Al Musawa M, Almohaizeie A, Almuhisen S, Damfu N, et\u00a0al. Ceftolozane-tazobactam vs. colistin for the treatment of infections due to multidrug-resistant Pseudomonas aeruginosa: a multicentre cohort study. J Glob Antimicrob Resist. 2022;28:288\u201394. https:\/\/doi.org\/10.1016\/j.jgar.2022.01.023.","journal-title":"J Glob Antimicrob Resist"},{"key":"1301_CR67","doi-asserted-by":"publisher","first-page":"441","DOI":"10.37201\/req\/006.2021","volume":"34","author":"A Pinilla-Rello","year":"2021","unstructured":"Pinilla-Rello A, Huarte-Lacunza R, Magall\u00f3n-Mart\u00ednez A, Cazorla-Poderoso L, Pereira-Blanco O, P\u00e9rez-Moreno M, et\u00a0al. [Utilization study in real clinical practice of ceftolozane\/tazobactam vs aminoglycosides and\/or colistin in the treatment of multirresistant or extremely resistant Pseudomonas aeruginosa]. Rev Esp Quimioter. 2021;34:441\u20139. https:\/\/doi.org\/10.37201\/req\/006.2021.","journal-title":"Rev Esp Quimioter"},{"key":"1301_CR68","doi-asserted-by":"publisher","DOI":"10.1128\/aac.02291-19","author":"SCJ Jorgensen","year":"2020","unstructured":"Jorgensen SCJ, Trinh TD, Zasowski EJ, Lagnf AM, Simon SP, Bhatia S, et\u00a0al. Real-world experience with ceftolozane-tazobactam for multidrug-resistant gram-negative bacterial infections. Antimicrob Agents Chemother. 2020. https:\/\/doi.org\/10.1128\/aac.02291-19.","journal-title":"Antimicrob Agents Chemother"},{"key":"1301_CR69","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1093\/cid\/ciz816","volume":"71","author":"JM Pogue","year":"2020","unstructured":"Pogue JM, Kaye KS, Veve MP, Patel TS, Gerlach AT, Davis SL, et\u00a0al. Ceftolozane\/Tazobactam vs polymyxin or aminoglycoside-based regimens for the treatment of drug-resistant Pseudomonas aeruginosa. Clin Infect Dis. 2020;71:304\u201310. https:\/\/doi.org\/10.1093\/cid\/ciz816.","journal-title":"Clin Infect Dis"},{"key":"1301_CR70","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.ijantimicag.2018.11.001","volume":"53","author":"M Bassetti","year":"2019","unstructured":"Bassetti M, Castaldo N, Cattelan A, Mussini C, Righi E, Tascini C, et\u00a0al. Ceftolozane\/tazobactam for the treatment of serious Pseudomonas aeruginosa infections: a multicentre nationwide clinical experience. Int J Antimicrob Agents. 2019;53:408\u201315. https:\/\/doi.org\/10.1016\/j.ijantimicag.2018.11.001.","journal-title":"Int J Antimicrob Agents"},{"key":"1301_CR71","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofy280","volume":"5","author":"JC Gallagher","year":"2018","unstructured":"Gallagher JC, Satlin MJ, Elabor A, Saraiya N, McCreary EK, Molnar E, et\u00a0al. Ceftolozane-tazobactam for the treatment of multidrug-resistant Pseudomonas aeruginosa infections: a multicenter study. Open Forum Infect Dis. 2018;5:ofy280. https:\/\/doi.org\/10.1093\/ofid\/ofy280.","journal-title":"Open Forum Infect Dis"},{"key":"1301_CR72","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1016\/j.idnow.2021.05.003","volume":"51","author":"B Castan","year":"2021","unstructured":"Castan B, Akrich B, Levy-Bachelot L, Amode A, Berthelot A, Mackosso C, et\u00a0al. Real-world evaluation of ceftolozane\/tazobactam therapy and clinical outcomes in France. Infect Dis Now. 2021;51:532\u20139. https:\/\/doi.org\/10.1016\/j.idnow.2021.05.003.","journal-title":"Infect Dis Now"},{"key":"1301_CR73","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1111\/jcpt.13623","volume":"47","author":"M Ronda","year":"2022","unstructured":"Ronda M, P\u00e9rez\u2010Recio S, Gonz\u00e1lez Laguna M, Tubau Quintano MDLF, Llop Talaveron J, Soldevila\u2010Boixader L, et\u00a0al. Ceftolozane\/tazobactam for difficult\u2010to\u2010treat gram\u2010negative infections: a real\u2010world tertiary hospital experience. Clin Pharm Ther. 2022;47:932\u20139. https:\/\/doi.org\/10.1111\/jcpt.13623.","journal-title":"Clin Pharm Ther"},{"key":"1301_CR74","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.106270","volume":"57","author":"B Balandin","year":"2021","unstructured":"Balandin B, Ballesteros D, Ruiz De Luna R, L\u00f3pez-Vergara L, Pintado V, Sancho-Gonz\u00e1lez M, et\u00a0al. Multicenter study of ceftolozane\/tazobactam for treatment of Pseudomonas aeruginosa infections in critically ill patients. Int J Antimicrob Agents. 2021;57:106270. https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.106270.","journal-title":"Int J Antimicrob Agents"},{"key":"1301_CR75","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1016\/S1473-3099(19)30403-7","volume":"19","author":"MH Kollef","year":"2019","unstructured":"Kollef MH, Nov\u00e1\u010dek M, Kivistik \u00dc, R\u00e9a-Neto \u00c1, Shime N, Martin-Loeches I, et\u00a0al. Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis. 2019;19:1299\u2013311. https:\/\/doi.org\/10.1016\/S1473-3099(19)30403-7.","journal-title":"Lancet Infect Dis"},{"key":"1301_CR76","unstructured":"Tran HA, Vu TNB, Trinh ST, Tran DL, Pham HM, Ngo THH, et\u00a0al. Resistance mechanisms and genetic relatedness among carbapenem-resistant Pseudomonas aeruginosa isolates from three major hospitals in Hanoi, Vietnam (2011\u201315). n.d."},{"key":"1301_CR77","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2022.106536","volume":"59","author":"B Baland\u00edn","year":"2022","unstructured":"Baland\u00edn B, Ballesteros D, Pintado V, Soriano-Cuesta C, Cid-Tovar I, Sancho-Gonz\u00e1lez M, et\u00a0al. Multicentre study of ceftazidime\/avibactam for gram-negative bacteria infections in critically ill patients. Int J Antimicrob Agents. 2022;59:106536. https:\/\/doi.org\/10.1016\/j.ijantimicag.2022.106536.","journal-title":"Int J Antimicrob Agents"},{"key":"1301_CR78","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofz522","volume":"6","author":"SCJ Jorgensen","year":"2019","unstructured":"Jorgensen SCJ, Trinh TD, Zasowski EJ, Lagnf AM, Bhatia S, Melvin SM, et\u00a0al. Real-world experience with ceftazidime-avibactam for multidrug-resistant gram-negative bacterial infections. Open Forum Infect Dis. 2019;6:ofz522. https:\/\/doi.org\/10.1093\/ofid\/ofz522.","journal-title":"Open Forum Infect Dis"},{"key":"1301_CR79","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.03108-23","volume":"12","author":"A El Ghali","year":"2024","unstructured":"El Ghali A, Kunz Coyne AJ, Lucas K, Tieman M, Xhemali X, Lau S, et\u00a0al. Cefiderocol: early clinical experience for multi-drug resistant gram-negative infections. Microbiol Spectr. 2024;12:e03108-23. https:\/\/doi.org\/10.1128\/spectrum.03108-23.","journal-title":"Microbiol Spectr"},{"key":"1301_CR80","doi-asserted-by":"publisher","first-page":"4427","DOI":"10.2147\/IDR.S475462","volume":"17","author":"CJ Clancy","year":"2024","unstructured":"Clancy CJ, Cornely OA, Marcella SW, Nguyen ST, Gozalo L, Cai B. Effectiveness and safety of cefiderocol in clinical practice for treatment of patients with gram-negative bacterial infections: US interim results of the PROVE study. Infect Drug Resist. 2024;17:4427\u201343. https:\/\/doi.org\/10.2147\/IDR.S475462.","journal-title":"Infect Drug Resist"},{"key":"1301_CR81","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1007\/s40121-024-01016-y","volume":"13","author":"DR Giacobbe","year":"2024","unstructured":"Giacobbe DR, Labate L, Russo Artimagnella C, Marelli C, Signori A, Di Pilato V, et\u00a0al. Use of cefiderocol in adult patients: descriptive analysis from a prospective, multicenter, cohort study. Infect Dis Ther. 2024;13:1929\u201348. https:\/\/doi.org\/10.1007\/s40121-024-01016-y.","journal-title":"Infect Dis Ther"},{"key":"1301_CR82","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2024.106376","volume":"90","author":"S Soueges","year":"2025","unstructured":"Soueges S, Faure E, Parize P, Lanternier-Dessap F, Lecuyer H, Huynh A, et\u00a0al. Real-world multicentre study of cefiderocol treatment of immunocompromised patients with infections caused by multidrug-resistant gram-negative bacteria: CEFI-ID. J Infect. 2025;90:106376. https:\/\/doi.org\/10.1016\/j.jinf.2024.106376.","journal-title":"J Infect"},{"key":"1301_CR83","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/S1473-3099(17)30747-8","volume":"18","author":"A Torres","year":"2018","unstructured":"Torres A, Zhong N, Pachl J, Timsit J-F, Kollef M, Chen Z, et\u00a0al. Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial. Lancet Infect Dis. 2018;18:285\u201395. https:\/\/doi.org\/10.1016\/S1473-3099(17)30747-8.","journal-title":"Lancet Infect Dis"},{"key":"1301_CR84","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/S1473-3099(20)30731-3","volume":"21","author":"RG Wunderink","year":"2021","unstructured":"Wunderink RG, Matsunaga Y, Ariyasu M, Clevenbergh P, Echols R, Kaye KS, et\u00a0al. Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis. 2021;21:213\u201325. https:\/\/doi.org\/10.1016\/S1473-3099(20)30731-3.","journal-title":"Lancet Infect Dis"},{"key":"1301_CR85","doi-asserted-by":"publisher","first-page":"2752","DOI":"10.1093\/jac\/dkad298","volume":"78","author":"M Piccica","year":"2023","unstructured":"Piccica M, Spinicci M, Botta A, Bianco V, Lagi F, Graziani L, et\u00a0al. Cefiderocol use for the treatment of infections by carbapenem-resistant gram-negative bacteria: an Italian multicentre real-life experience. J Antimicrob Chemother. 2023;78:2752\u201361. https:\/\/doi.org\/10.1093\/jac\/dkad298.","journal-title":"J Antimicrob Chemother"},{"key":"1301_CR86","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00907-24","volume":"68","author":"DA Hareza","year":"2024","unstructured":"Hareza DA, Cosgrove SE, Bonomo RA, Dzintars K, Karaba SM, Hawes AM, et\u00a0al. Clinical outcomes and emergence of resistance of Pseudomonas aeruginosa infections treated with ceftolozane-tazobactam versus ceftazidime-avibactam. Antimicrob Agents Chemother. 2024;68:e0090724. https:\/\/doi.org\/10.1128\/aac.00907-24.","journal-title":"Antimicrob Agents Chemother"},{"key":"1301_CR87","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0000000000001334","author":"M Gatti","year":"2025","unstructured":"Gatti M, Cojutti PG, Rinaldi M, Ambretti S, Giannella M, Viale P, et\u00a0al. Utility of a TDM-guided expert clinical pharmacological advice program for optimizing the use of novel beta-lactam\/beta-lactamase inhibitor combinations and cefiderocol in a tertiary university hospital: an interim analysis. Ther Drug Monit. 2025. https:\/\/doi.org\/10.1097\/FTD.0000000000001334.","journal-title":"Ther Drug Monit"}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-026-01301-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-026-01301-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-026-01301-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T17:56:27Z","timestamp":1771696587000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-026-01301-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,31]]},"references-count":87,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["1301"],"URL":"https:\/\/doi.org\/10.1007\/s40121-026-01301-y","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,31]]},"assertion":[{"value":"28 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Aur\u00e9lien Dinh reports consulting fees from Shionogi Eumedica, Pfizer, and Advanz Pharma. Katy Jeannot reports research funding from Thermo Fisher Scientific, MSD, Shionogi, Pfizer, bioMerieux, and Bacteriomic. Eric Kipnis reports consulting fees from Shionogi, Advanz, LFB Biomedicaments, Astra Zeneca, Pfizer, and MSD. Jean-Ralph Zahar reports consulting fees from Pfizer and Shionogi. Alexandre Bleibtreu reports consulting fees from Advanz, Pfizer, Eumedica, and Shionogi. Youssef Bennis reports consulting fees from Shionogi and Novartis. Herv\u00e9 Dupont reports consulting fees from Pfizer, Gilead, MSD, Mundipharma, Shionogi, and Paratek. Arnaud Friggeri reports consulting fees from Shionogi.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Institutional review board approval was not required, as the study did not involve patient data and no database was established. All nine panel participants consented to participate and to\u00a0the publication. However, one participant requested not to be included among the authors for personal reasons. Data from the REA-REZO (\n                      \n                      ) and GERPA networks are identifiable and permission is required for access.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}